Literature DB >> 24321511

N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

B Torres1, A E Ruoho2.   

Abstract

The 20 amino acid (AA) N-terminus of the vesicular monoamine transporter 2 (VMAT2) was examined as a regulator of VMAT2 function. Removal of the first 16 or 19 AAs of the N-terminus resulted in a molecule with reduced ability to sequester [(3)H]-5HT. A glutathione-S-transferase-construct of the N-terminus underwent phosphorylation in the presence of PKC at serines 15 and 18. These putative phosphorylation sites were examined for effects on function. Phospho-mimetic substitution of serines 15 and 18 with aspartate in the full-length VMAT2 resulted in reduced [(3)H]-5HT sequestration and reduced methamphetamine (METH)-stimulated efflux of preloaded [(3)H]-5HT. In contrast, mutation of serines 15 and 18 to alanines maintained intact net substrate sequestration but eliminated METH-stimulated efflux of pre-accumulated [(3)H]-5HT. In summary, these data suggest a model in which the VMAT2 N-terminus regulates monoamine sequestration.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AAs; AMPH; BSA; CPM; CaCl(2); DAT; DPM; GST; HA; KLH; KSR; M-PMTs; METH; MgCl(2); PBS; PD; PIP(2); PKC; PS; PVDF; Parkinson’s disease; RSP; SDS–PAGE; SH; TBZ; TBZ-OH; VMAT2; [(3)H]-tetrabenazine-OH; amino acids; amphetamine; bovine serum albumin; calcium chloride; counts per minute; decays per minute; diolyl phosphatidyl serine; dopamine transporter; efflux; glutathione-S-transferase; hemagglutinin; kDa; ketansarin; keyhole limpet hemocyanin; kilodalton; kinase; magnesium chloride; methamphetamine; monoamine; monoamine plasma membrane transporters; pN-term Ab; phosphate-buffered saline; phosphatidylinositol-4,5-bisphosphate; phospho-specific N-term antibody; polyvinylidene fluoride; protein kinase C; reserpine; sodium dodecyl sulfate–polyacrylamide gel; sucrose HEPES; tetrabenazine; transporter; vesicular monoamine transporter 2

Mesh:

Substances:

Year:  2013        PMID: 24321511      PMCID: PMC3926813          DOI: 10.1016/j.neuroscience.2013.11.059

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  50 in total

1.  Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter.

Authors:  M K Sievert; A E Ruoho
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease.

Authors:  Charles Glatt; Maricel Almonte; Travis Taylor; Robert H Edwards; Nelson Freimer; Caroline Tanner
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

3.  Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms.

Authors:  Mark A Cervinski; James D Foster; Roxanne A Vaughan
Journal:  J Biol Chem       Date:  2005-10-04       Impact factor: 5.157

4.  The vesicular monoamine transporter 2 contains trafficking signals in both its N-glycosylation and C-terminal domains.

Authors:  Jia Yao; Louis B Hersh
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

5.  Interaction of amphetamines and related compounds at the vesicular monoamine transporter.

Authors:  John S Partilla; Allison G Dempsey; Ameet S Nagpal; Bruce E Blough; Michael H Baumann; Richard B Rothman
Journal:  J Pharmacol Exp Ther       Date:  2006-07-11       Impact factor: 4.030

Review 6.  Mechanisms of neurotransmitter release by amphetamines: a review.

Authors:  David Sulzer; Mark S Sonders; Nathan W Poulsen; Aurelio Galli
Journal:  Prog Neurobiol       Date:  2005-04       Impact factor: 11.685

7.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

Authors:  Charles E Glatt; Angelika D Wahner; Daniel J White; Andres Ruiz-Linares; Beate Ritz
Journal:  Hum Mol Genet       Date:  2005-12-08       Impact factor: 6.150

8.  The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake.

Authors:  Irene Brunk; Christian Blex; Sivaramakrishna Rachakonda; Markus Höltje; Sandra Winter; Ingrid Pahner; Diego J Walther; Gudrun Ahnert-Hilger
Journal:  J Biol Chem       Date:  2006-08-22       Impact factor: 5.157

9.  Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport.

Authors:  Jacob U Fog; Habibeh Khoshbouei; Marion Holy; William A Owens; Christian Bjerggaard Vaegter; Namita Sen; Yelyzaveta Nikandrova; Erica Bowton; Douglas G McMahon; Roger J Colbran; Lynette C Daws; Harald H Sitte; Jonathan A Javitch; Aurelio Galli; Ulrik Gether
Journal:  Neuron       Date:  2006-08-17       Impact factor: 17.173

Review 10.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

View more
  9 in total

Review 1.  Functional mechanisms of neurotransmitter transporters regulated by lipid-protein interactions of their terminal loops.

Authors:  George Khelashvili; Harel Weinstein
Journal:  Biochim Biophys Acta       Date:  2015-04-04

2.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

Review 3.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 4.  Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action.

Authors:  Caline S Karam; Jonathan A Javitch
Journal:  Adv Pharmacol       Date:  2017-10-25

5.  Pharmacoterrorism: the potential role of psychoactive drugs in the Paris and Tunisian attacks.

Authors:  Guillaume Fond; Oliver Howes
Journal:  Psychopharmacology (Berl)       Date:  2016-01-11       Impact factor: 4.530

6.  Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.

Authors:  Zachary Freyberg; Mark S Sonders; Jenny I Aguilar; Takato Hiranita; Caline S Karam; Jorge Flores; Andrea B Pizzo; Yuchao Zhang; Zachary J Farino; Audrey Chen; Ciara A Martin; Theresa A Kopajtic; Hao Fei; Gang Hu; Yi-Ying Lin; Eugene V Mosharov; Brian D McCabe; Robin Freyberg; Kandatege Wimalasena; Ling-Wei Hsin; Dalibor Sames; David E Krantz; Jonathan L Katz; David Sulzer; Jonathan A Javitch
Journal:  Nat Commun       Date:  2016-02-16       Impact factor: 14.919

Review 7.  Protein Kinase C Isozymes and Autophagy during Neurodegenerative Disease Progression.

Authors:  Humeyra Nur Kaleli; Ebru Ozer; Veysel Ogulcan Kaya; Ozlem Kutlu
Journal:  Cells       Date:  2020-02-27       Impact factor: 6.600

8.  Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum.

Authors:  Laszlo G Harsing; Joseph Knoll; Ildiko Miklya
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

9.  Spontaneous inward opening of the dopamine transporter is triggered by PIP2-regulated dynamics of the N-terminus.

Authors:  George Khelashvili; Nathaniel Stanley; Michelle A Sahai; Jaime Medina; Michael V LeVine; Lei Shi; Gianni De Fabritiis; Harel Weinstein
Journal:  ACS Chem Neurosci       Date:  2015-08-17       Impact factor: 4.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.